fb-pixel Skip to main content
Health and biotech

Latest stories

More biotech and health care stories


Hospitals in R.I. have tenants that are not exempt from real estate taxes. Lawmakers say it’s time for them to pay.

Up for a vote in the House on Thursday, proposed legislation would require businesses that are not tax exempt – but are renting space in nonprofit buildings – to pay property taxes.

FDA delays decision on Sarepta’s controversial gene therapy for muscular dystrophy

The agency was scheduled to rule on the Cambridge company’s medicine by Monday, but will now wait until June 22.

Billionaire Tim Springer donates $210 million to protein research nonprofit

The early investor in Moderna has made one of the largest donations in local life sciences to the Boston-based Institute for Protein Innovation.

After ransomware attack, state’s second-largest health insurer says patient data stolen

The data taken may contain personal information and potential protected health information, including names, Social Security numbers, and provider taxpayer identification numbers.

Blueprint Medicines says its newly approved drug for a rare life-threatening disorder could be a blockbuster

The Cambridge biotech’s treatment combats an immune and blood condition that causes severe allergic reactions to ordinary things, like a whiff of perfume or an elevated heart rate.

Black children are more likely to have asthma than kids of any other race in America

Asthma is treatable. But Black children often struggle to get treatment, and are more likely than white kids to end up in the emergency room with asthma symptoms.


Learning to treat long COVID could help those struggling with ME/Chronic Fatigue Syndrome, too

Some experts say the current crisis of long COVID is related to our government’s neglect of similar post-acute infection chronic illnesses like ME/CFS in decades past.

Under pressure from patients, FDA faces tough choices on experimental gene therapy

The prospect of “accelerated approval” for a single-dose treatment for Duchenne muscular dystrophy has drawn criticism from some experts who say the FDA is loosening its standards.